全球生物技术巨头CSL有限公司近日宣布，公司已启动与相关药品监管部门的密切沟通，共同探讨保障基因疗法Hemgenix长期稳定供应的战略方案。这一举措旨在应对潜在供应链挑战，确保这款突破性血友病B治疗药物能够持续满足全球患者的临床需求。
通过建立多方协作机制，CSL将优化从原料采购到成品配送的全链条管理。公司表示将采用前瞻性供应规划，结合动态库存监控体系，构建具有韧性的供应链网络。目前Hemgenix已在美国、欧盟等主要市场获得上市批准，其创新疗法有望为重度血友病B患者提供一次性根治方案。
此次战略合作凸显了CSL对患者用药可及性的长期承诺。随着基因治疗领域的快速发展，保障尖端疗法的稳定供应已成为生物制药行业的重要议题。CSL将通过技术创新与监管协作的双重路径，持续推动罕见病治疗领域的进步。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.